Latest Breaking News On - Systemic lupus erythematosus responder index - Page 4 : comparemela.com

PALS program effective in ensuring diverse representation in lupus clinical trials

The Lupus Research Alliance and its affiliate Lupus Therapeutics presented data at ACR Convergence 2022 with results showing the effectiveness of a pilot peer education program called the Patient Advocates for Lupus Studies (PALS), in increasing knowledge, perception, and willingness among people with Systemic Lupus Erythematosus (SLE) to participate in clinical trials.

Promising Data Shows Lupus Research Alliance Peer Education Program Increases Willingness to Join Clinical Trials Among Diverse Patient Population

/PRNewswire/ The Lupus Research Alliance and its affiliate Lupus Therapeutics will present data at ACR Convergence 2022 with results showing the.

Lilly Ends Baricitinib Lupus Program, Provides Update on Atopic Dermatitis sNDA

Lilly has decided to discontinue the phase 3 development program for baricitinib in adults with active systemic lupus erythematosus.

Idorsia Pharmaceuticals Ltd: Idorsia to advance cenerimod into Phase 3 development for treatment of patients with systemic lupus erythematosus

Ad hoc announcement pursuant to Art. 53 LR Cenerimod 4 mg showed clinically meaningful improvement in the mSLEDAI-2K primary efficacy endpoint and other measures of efficacy, consistent with the effect

GNW: Idorsia to advance cenerimod into Phase 3 development for treatment of | Newsticker